The PennZone

  • Home
  • Non-profit
  • Technology
  • Entertainment
  • Business
  • Education
  • Marketing
  • Health
  • Construction

ExpressCells Named Most Fundable Company by Pepperdine Graziadio Business School
The PennZone/10088820

Trending...
  • The J. Wes Project Celebrates 11 Years of Love, Music & Inspiration
  • Philadelphia Community Invited to Unite for Praise-A-Thon Summer Concert Benefiting Cobbs Creek
  • Cover Story about Matthew Cossolotto – Author of Harness Your PromisePower -- Published in July 2026 Enterprise World Magazine
PHILADELPHIA - PennZone -- ExpressCells, Inc., a biotechnology company that creates advanced cell lines for research, was awarded a silver designation on the Pepperdine Graziadio Business School's third annual Most Fundable Companies® List. ExpressCells competed against over 4,500 early-stage U.S. startups spanning all 50 states, all with less than $10 million in annual revenue, to be named among a list of twenty. The Most Fundable Companies initiative is designed to recognize exceptional entrepreneurs who are solving today's problems with inventive solutions and are also seeking investment capital to fuel their company's growth.

"Since starting ExpressCells in 2018, we've been focused on helping biological researchers conduct better experiments.. The Most Fundable Companies initiative provided us with a data-driven analysis that we have already incorporated into our fundraising activities," said Matt Handel, CEO. "It's validating that Pepperdine Graziadio Business School recognizes entrepreneurs throughout the country and provides resources to assist startups in securing private capital to accelerate meaningful innovation across industries and communities."

More on The PennZone
  • Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
  • Aderra Opens in Magnolia, Texas, Offering a New Model for 62+ Homeownership
  • What's New in Hokkaido, Autumn 2026
  • CRG Awarded NASA SEWP VI Contracts in Categories B and C
  • Heidi G. Villari of The Villari Firm, PLLC Named to Super Lawyers for the Tenth Consecutive Year

The Most Fundable Companies initiative involved a multi-phase assessment that evaluated several company variables, including financial projections, market opportunity, intellectual property, and the strength of the management team, all of which were used to produce a fundability score. The Most Fundable Companies were evaluated and selected based on their readiness for private investment. Most Fundable Companies is powered by The Venture Alliance.

As a winner on the Most Fundable Companies List, ExpressCells will be profiled on Entrepreneur.com and be featured in the December print issue of the magazine. For a complete list of the winners, visit www.pepperdine.edu/mfc-list, where you can vote for ExpressCells as the "crowd favorite" through November 1.

The Pepperdine Most Fundable Companies list does not represent an offer to sell securities. It neither constitutes investment advice, nor is an endorsement of any particular product or service. Pepperdine University is not a broker-dealer and does not perform services provided by a broker-dealer, including but not limited to any financial or investment advising.

More on The PennZone
  • Elevate Your Sneakers With Crep Protect Trek Laces
  • Meet Privateer: Tucson's High-Tech Security Force Built With Paramilitary Precision
  • Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC)

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its uses it proprietary genome editing technology, in combination with CRISPR/Cas9, to create advanced, knock-in cell lines to enhance drug discovery and other biological research. It shortens the time for delivery of knock-in cell lines by up to 75% relative to current technologies. The speed of the process allows ExpressCells to insert one to three genes into the same cell line. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines.

ExpressCells' genetic engineering technology was invented at the Temple University School of Pharmacy by Oscar Perez-Leal, MD. ExpressCells holds a global, exclusive license on this technology. For more information, visit xpresscells.com (http://www.xpresscells.com/).

Contact
Matt Handel
***@xpresscells.com


Source: ExpressCells

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Fatal FOMO May be Your Last Roll of the Dice
  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
  • Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio
  • Community Partnership Brings Live Theater to 150+ Young People
  • Best Rainbow Baby Charities That Support Bereaved Parents After Pregnancy Loss: A Complete Guide
  • PokerStars & Ladbrokes veteran buys into Finnish news media Rahapelisanomat
  • Former Judge Chris Oldner Honored as Best Lawyer by "D Magazine" for 6th Straight Year
  • Missouri Hemp Businesses File Federal Lawsuit Challenging HB 2641
  • Boston Industrial Solutions Launches New Citrine® SA1-370 Silicone Glue for Permanent Adhesion
  • Northeast Airlines Launches New Asset Management Group
  • AI Visibility Labs LLC - Dallas Texas - July 16 2026
  • NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)
  • ET&T Adds Senior Technical Voice Engineer to Strengthen Local Team
  • Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers
  • Where Is Your Faith The Movie and Sountrack
  • Bynn Intelligence Ranks #1 in NIST Child Online Safety Evaluation for Ages 13–16
  • Rev-O-Box™ Launches Reversible Shipping Box That Instantly Becomes a Premium Gift Box
  • Las Vegas Estate Firm Ghandi Deeter Blackham Offers Insight on Tony Hsieh's Contested $500 Million Will
  • CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe

Popular on PennZone

  • Proper Sky Named to the 2026 MSP 501
  • Slotozilla Introduces a Centralized Resource for World Cup Bonus Offers
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • Dentists launch independent platform to help practices choose the right technology
  • 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
  • New "Lakeside Picnic Ride" Package in Japan's Lake Chuzenji region of Nikko: July 1- November 30, 2026
  • RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
  • Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules
  • Vierra Communities Adds Operations of Two Skilled Nursing Facilities in the DC Metro Area
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love

Similar on PennZone

  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us